Matching slides 303,780
Current window 213,001-213,030
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all

Component

213,001-213,030 of 303,780

filter-aware
10
The slide outlines a multi-part clinical trial design with specific dosing cohorts and eligibility requirements.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution Approach1 hit
11
The chart displays efficacy data for a drug candidate (pegtarviliase) across different dosage cohorts.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Solution Approach1 hit
12
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
13
ADA stands for Anti-Drug Antibodies.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
14
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
The slide uses a timeline-based progression of symptoms to illustrate the severity of the disease.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
16
The slide uses a two-column layout to contrast commercial/regulatory status with clinical trial outcomes.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
17
Includes box plots for arginine levels and bar charts for patient normalization rates.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
18
Clinical trial data presentation with statistical significance markers and MCID thresholds.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
19
The slide uses a heatmap to display individual patient outcomes across four metrics (pArg, GMFM-E, 2MWT, GMFM-D).Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
20
The slide presents clinical trial safety data comparing Pegzilarginase to a placebo group.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
21
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
22
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
23
The slide presents a standard quarterly financial comparison (P&L summary) and balance sheet highlights.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a biological pathway diagram to explain the mechanism of action of the drug candidate.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · TractionLoop · Before After1 hit
27
The slide includes experimental design details and statistical significance markers (p < 0.05).Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
28
Includes survival curve (Kaplan-Meier) and pharmacodynamic response (tHcy levels over time).Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
29
Includes histological images of liver tissue and a dot plot showing bone mineral density (BMD) improvement.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
30
The table displays mean/SD, range, and counts/percentages for Pegzilarginase (n=21), Placebo (n=11), and Overall (N=32).Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
31
Data includes Plasma Arginine, GMFCS level, GMFM-E, and 2MWT metrics.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
32
The chart is a box-and-whisker plot showing longitudinal data from baseline through 56 weeks.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
33
Includes both continuous mean change data and categorical responder analysis.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
34
Includes a study design timeline at the bottom right and MCID reference lines on the GMFM-E chart.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
35
Slide details GMFCS classification levels and GMFM/Timed Walk Test methodologies.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · Traction1 hit
38
The slide uses a split-screen layout: left side is market sizing/geographic distribution, right side is a 2x2 matrix of launch activities.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Aeglea BioTherapeutics
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
01
Slide 1
Aeva | Results Presentation Deck | 11 slidesAeva | Results Presentation Deck | 11 slides · Aeva
Conference presentation Investor relations 1 hit
02
Aeva | Results Presentation Deck | 11 slidesAeva | Results Presentation Deck | 11 slides · Aeva
Conference presentation Investor relations 1 hit
03
Aeva | Results Presentation Deck | 11 slidesAeva | Results Presentation Deck | 11 slides · Aeva
Conference presentation Investor relations 1 hit
04
Aeva | Results Presentation Deck | 11 slidesAeva | Results Presentation Deck | 11 slides · Aeva
Conference presentation Investor relations Beat · Attention1 hit
05
Aeva | Results Presentation Deck | 11 slidesAeva | Results Presentation Deck | 11 slides · Aeva
Conference presentation Investor relations Beat · Need1 hit